Алынды: 04.12.2023 Қабылданды: 31.01.2024 Онлайн жарияланды: 29.02.2024
УДК 616.9(043)
DOI 10.53511/PHARMKAZ.2024.23.13.016
Н. ЕЖЕЙ 1, C.Б. КАЛМАХАНОВ 2
1,2 Әл-Фараби атындағы Қазақ ұлттық университеті, Алматы, Қазақстан
CЕРОПОЗИТИВТІК H.PYLORI ЖІТІ КОРОНАРЛЫҚ СИНДРОМНЫҢ ҚАУІП
ФАКТОРЫ РЕТІНДЕ
Түйін: Helicobacter pylori әлем халқының 70%-дан астамы жұқтырған, кең таралған бактерия. Cеропозитивтік H.pylori-тті коронарлық синдромның қауіп факторы ретінде, қабыну және метаболикалық жолдары арқылы әсер етеді. Бұл мақалада соңғы 15 жылда шыққан Pubmed, Scopus, CNKI.
NET базасынан ізделген pylori-нің ACS туғызатын патогендік механизмімен байланысты биологиялық көрсеткіштер және Hp инфекциясы бар науқастарда ACS болуының емдеу шаралары туралы деректер ұсынылады.
Түйінді сөздер: Helicobacter pylori, жіті коронарлық синдром, патогендік механизм, биологиялық көрсеткіштер, алдын-алу және емдеу әдістері.
ӘДЕБИЕТТЕР ТІЗІМІ
1 James K.Y. Hooi, Wan Ying Lai, Wee Khoon Ng, Michael M.Y.Suen.et al.Global Prevalence of Helicobacter pylori Infection: Systematic Review and MetaAnalysis. Gastroenterology. 2017 Aug;153(2):420-429.
2 Linda Mezmale, Inese Polaka, Dace Rudzite.Prevalence and Potential Risk Factors of Helicobacter pylori Infection among Asymptomatic Individuals in
Kazakhstan. Asian Pacific Journal of Cancer Prevention. 2021; 22 (2): 597-602.
3 M.A.Mendall, P.M.Goggin, N. Molineaux.et al.Relation of Helicobacter pylori infection and coronary heart disease.Br Heart J. 1994 May; 71(5): 437-9.
4 M. Kowalski a, W. Rees a, P.C. Konturek.et al.Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to
prior myocardial infarction and unstable angina.Digestive and Liver Disease. 2002 June; 34(6):398-402.
5 Zhao Yanying, Cheng Haitao, Wang Zhijun. et al. Coronary atherosclerotic heart disease and the association with H. pylori infection [J]. World Chinese
Digestion Journal, 2016,24 (10): 1613
6 Magdalena Chmiela, Adrian Gajewski, Karolina Rudnicka. Helicobacter pylori vs coronary heart disease — searching for connections.World J Cardiol. 2015
April 26; 7(4): 187-203.
7 WU Yuyan,HUANG Bingsheng, CHENG Ying. et al.Effect of CagA-positive Helicobacter pylori strains on coronary atherosclerosis in patients with acute
coronary syndrome. South China Journal of Cardiovascular Diseases. 2010 August;16(4):304-307.
8 Anita Jukic, Dorotea Bozic, Dusko Kardum. et al.Helicobacter pylori infection and severity of coronary atherosclerosis in patients with chronic coronary artery
disease.Therapeutics and Clinical Risk Management.2017:13 933–938.
9 Sun Jing, Pooja Rangan, Srinidhi Subraya Bhat, Longjian Liu.A Meta-Analysis of the Association between Helicobacter pylori Infection and Risk of Coronary
Heart Disease from Published Prospective Studies.Helicobacter. 2016 Feb;21(1):11-23.
10 Fang Yizhen, Fan Chunming, Xie Huabin. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: A systematic review and metaanalysis. Medicine. 2019;98:50(e18348).
11 M. Kowalski, M.Pawlik, J.W. Konturek .et al. Helicobacter pylori infection in coronary artery disease.J Physiol Pharmacol. 2006 Sep; 57 Suppl 3: 101-11.
12 Sun Lichang , Zheng Haoxiao ,Qiu Min .Helicobacter pylori infection and risk of cardiovascular disease. Helicobacter. 2023; 28: e12967.
13 Marcio Mossmann, Marco Vugman Wainstein, Stéfani Mariani. Increased serum IL-6 is predictive of long-term cardiovascular events in high-risk patients
submitted to coronary angiography: an observational study. Diabetology & Metabolic Syndrome. 2022; 14:125.
14 Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72:3320–
3331.
15 Wael Sumaya, Lars Wallentin, Stefan K. James.et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome:
a PLATO substudy.European Heart Journal. 2018; 39:1078–1085.
16 Li Yan, He Zhihua, Li Chaowei, YaoZhenguo.The study of the relationship between heliconbacter pylori and acute coronary syndrome.Int J LabMed. 2013
March;34(6).
17 Yoshitaka Furuto, Mariko Kawamura, Jumpei Yamashita.et al.Relationship Between Helicobacter pylori Infection and Arteriosclerosis.International Journal
of General Medicine 2021:14 1533–1540.
18 Aslihan Calim, Fatma Paksoy Turkoz, Yuksel Asli Ozturkmen.et al.The Relation between Homocysteine Levels in Patients with Acute Coronary Syndrome
and Grace Score.Med Bull Sisli Etfal Hosp 2020;54(3):346–350.
19 GU Shangwu, FENG Hong, CHEN Yao.et al.Correlation analysis of serum homocysteine, uric acid levels and severity degree of coronary artery disease
in patients with coronary heart disease
20 and diabetes mellitus.China Modern Medicine. 2021 September;28:27.
21 Piort Skrzupczyk , Anna Ozimek, Anna Ofiara.Markers of endothelial injury and subclinical inflammation in children and adolescents with primary
hypertension.Central European Journal of Immunology. 2019; 44(3).
22 Yousef Rasmi,Hadi Rouhrazi, Ebrahim Khayati-Shal.Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in
patients with cardiac syndrome .biomedical journal. 2016; 39339: e345.
23 Riccardo Negrini, Vincenzo Villanacci , Claudio Poiesi .et al.Anti-Glycan Autoantibodies Induced by Helicobacter pylori as a Potential Risk Factor for
Myocardial Infarction.Frontiers in Immunology. 2020 April;11: 597.
24 Agnieszka Matusiak, Maciej Chałubiński, Marlena Broncel.Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart
disease in terms of humoral immune response and inflammation.Arch Med Sci. 2016; 12, 1: 45–54.
25 Zhao Huilin, Ji Xiaofei, Zhang Yanli.et al.Analysis of interaction between Helicobacter pylori UreB and its charreone Hsp60. Journal of PathlogenBiology.
2016;11(11):977-981.
26 Jiunn Wei Wang, Kuo Lun Tseng, Chien Ning Hsu.et al.Association between Helicobacter pylori
27 eradication and the risk of coronary heart diseases.PLoS ONE.2018;13(1):e0190219.
28 Sarah Wernly, Georg Semmler,Andreas Völkerer.et al.Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good
Helicobacter?Helicobacter. 2022;27:e12928.
29 Kiyoshi Ashida, Youichirou Honda, Katsuyuki Sanada.et al.The safety and effectiveness of vonoprazanbased Helicobacter pylori eradication therapy; a
prospective post-marketing surveillance.Exprt Option On Drug Safety.2019; 18( 12):1255–1261.
30 Paúl A. Cárdenas, Daniela Garcés, Belén Prado-Vivar.Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori
infection on gut microbiome.European Journal of Clinical Microbiology & Infectious Diseases.2020 March.
31 Xie Jie.Effect of Anti-Helicobacter pylori Therapy on Inflammatory Markers in Patients with Helicobacter pylori Infection in Acute Coronary Syndrome.Strait
Pharmaceutical Journal.2022;34(10).
32 Shangling Wua,Pinning Fen, Wanlin Li.Dietary Folate, Vitamin B6, and Vitamin B12 and Risk of Cardiovascular Diseases among Individuals with Type 2
Diabetes: A Case-Control Study.Ann Nutr Metab 2023;79:5–15
33 Jue Yang, Hui Song, Kun Cao.et al.Comprehensive analysis of Helicobacter pylori infection-associated diseases based on miRNA-mRNAinteraction network.
Briefings in Bioinformatics. 2019; 20(4):1492–1501.
34 Lichang Sun,Haoxiao Zheng, Min Qiu.Helicobacter pylori infection and risk of cardiovascular disease.Helicobacter. 2023;28:e12967.
35 Jonatan Wärme, Martin Sundqvist, Katarina Mars.et al.Helicobacter pylori screening in clinical routineduring hospitalization for acute myocardial infarction.
Am Heart J 2021;231:105–109.Ann Nutr Metab 2023;79:5–15.
